Skip to main content
Guhan Pharmaceutical Group Co., Ltd. logo

Guhan Pharmaceutical Group Co., Ltd. — Investor Relations & Filings

Ticker · 000590 ISIN · CNE000000701 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,714 across all filing types
Latest filing 2025-10-29 Board/Management Inform…
Country CN China
Listing Shenzhen Stock Exchange 000590

About Guhan Pharmaceutical Group Co., Ltd.

https://www.tuspharma.cn

Guhan Pharmaceutical Group Co., Ltd. specializes in the research, development, production, and sale of traditional Chinese medicine (TCM) and health-related products. The company is widely recognized for its flagship product, Guhan Yangsheng Jing, which is formulated based on ancient health preservation prescriptions discovered in the Mawangdui Han Dynasty Tombs. Its product portfolio includes oral liquids, tablets, and capsules designed to enhance vitality, support kidney function, and promote overall longevity. The organization integrates classical medical theories with modern pharmaceutical manufacturing processes to ensure product efficacy and safety. Beyond its core TCM offerings, the group engages in the production of chemical drugs and health supplements, targeting markets seeking natural wellness solutions. The company emphasizes the preservation of cultural heritage through the modernization of ancient medical wisdom.

Recent filings

Filing Released Lang Actions
关于补选公司第十届董事会独立董事的公告
Board/Management Information Classification · 100% confidence The document is an announcement regarding the election of an independent director to the company's board. It includes details about the candidate's qualifications and confirms compliance with relevant laws and regulations. There is no financial data, no report or presentation content, and it specifically concerns a change in the board of directors. Therefore, it fits the category of Board/Management Information (MANG). The document length is short and focused on this announcement, confirming it is not a full report or other filing type.
2025-10-29 Chinese
关于修改公司章程的公告
Governance Information Classification · 95% confidence The document is a detailed announcement regarding amendments to the company's Articles of Association (公司章程). It includes extensive legal references, comparisons of old and new articles, and explanations of the reasons for the amendments. The content focuses on governance structure, shareholder rights, board responsibilities, and compliance with updated regulatory guidelines. This type of document is typically classified as Governance Information (CGR) because it details the company's internal rules, board structure, and governance practices rather than being a financial report, meeting presentation, or voting result announcement. The document length and detail confirm it is the actual governance document, not just an announcement of its publication.
2025-10-29 Chinese
独立董事候选人声明与承诺(罗怀青)
Board/Management Information Classification · 95% confidence The document is a detailed declaration and commitment statement by an independent director candidate for a company's board. It includes statements of compliance with legal and regulatory requirements for independent directors, qualifications, and commitments to fulfill duties. There is no financial data, no report of financial results, no voting results, no announcement of a meeting, no audit information, and no mention of any other report type. This document is related to board/management information, specifically about a candidate for the board of directors. Therefore, the appropriate classification is Board/Management Information (MANG). The document length is 4428 characters, which is sufficient for a detailed statement but not a full report. Confidence is high due to the clear nature of the content.
2025-10-29 Chinese
关于拟签署《商标普通许可及转授权合同》暨关联交易的公告
Regulatory Filings Classification · 95% confidence The document is an announcement regarding a proposed related-party transaction involving the signing of a trademark license and sublicensing agreement. It details the parties involved, the terms of the agreement, the approval process by the board and independent directors, and the need for shareholder approval. There are no financial statements or detailed financial performance data presented. The document is a formal announcement of a corporate action related to a contract and related-party transaction, not a financial report or earnings release. It fits best under the category of Regulatory Filings (RNS) as it is a general regulatory announcement about a related-party transaction and contract signing.
2025-10-29 Chinese
关于拟签署日常经营关联交易协议的公告
Regulatory Filings Classification · 95% confidence The document is an announcement regarding the proposed signing of a routine related-party transaction agreement between the company and its related party. It details the nature of the transaction, parties involved, pricing, approval process, and the need for shareholder approval. The document is a formal disclosure of a related-party transaction proposal, not a financial report, earnings release, or management discussion. It is not a report publication announcement since it contains substantive information about the transaction itself. This fits the category of a Regulatory Filing (RNS) as it is a general regulatory announcement about a related-party transaction that does not fit into more specific categories like capital update or management changes.
2025-10-29 Chinese
第十届监事会临时会议决议公告
Regulatory Filings Classification · 95% confidence The document is an announcement of resolutions passed at a temporary meeting of the 10th Supervisory Board of Qidi Pharmaceutical Group Co., Ltd. It includes the approval of the 2025 third quarter report, but does not contain the report itself. It also discusses approval of related party transactions and mentions that these matters will be submitted to a shareholders' meeting for further approval. The document is short (1056 characters) and serves as a formal announcement of meeting decisions rather than a full financial report or detailed management discussion. Therefore, it fits best as a Regulatory Filing (RNS) since it is a general regulatory announcement about board resolutions and related transactions without substantive financial data or full report content.
2025-10-29 Chinese

Browse filings by year

28 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.